Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Camp4 Therapeutics (CAMP) · oqro.io/stocks/CAMP · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Insider trades · 28
17 routine filings (option exercises, shares withheld for taxes, grants, gifts) are not listed here. Show them
Since the trade −4.3% · S&P 500 −10.1% · to Nov 20
Bought 44% below the 52-week high, RSI 44, 12% under its 200-day average
The CFO of Camp4 Therapeutics paid $40K out of pocket for Camp4 Therapeutics shares. 3 other people at Camp4 Therapeutics bought some too, in the same month.
10 days before resultsTraded Aug 3 · filed 2 days later
Since the trade −10.0% · S&P 500 −9.0% · to Nov 20
Bought 41% below the 52-week high, RSI 59, 5% under its 200-day average
A Camp4 Therapeutics director paid $27K out of pocket for Camp4 Therapeutics shares. 3 other people at Camp4 Therapeutics bought some too, in the same month. Shares held went up 10% with this purchase.
10 days before resultsTraded Aug 3 · filed 2 days later
Since the trade −10.0% · S&P 500 −9.0% · to Nov 20
Bought 41% below the 52-week high, RSI 59, 5% under its 200-day average
Camp4 Therapeutics's Chief Medical Officer paid $11K out of pocket for Camp4 Therapeutics shares. 3 other people at Camp4 Therapeutics bought some too, in the same month. Shares held went up 108% with this purchase.
10 days before resultsTraded Aug 3 · filed 2 days later
Since the trade −10.0% · S&P 500 −9.0% · to Nov 20
Bought 41% below the 52-week high, RSI 59, 5% under its 200-day average
The CFO of Camp4 Therapeutics paid $11K out of pocket for Camp4 Therapeutics shares. 3 other people at Camp4 Therapeutics bought some too, in the same month. Shares held went up 10% with this purchase.
10 days before resultsTraded Aug 3 · filed 2 days later
Since the trade −10.0% · S&P 500 −9.0% · to Nov 20
Bought 41% below the 52-week high, RSI 59, 5% under its 200-day average
The CEO of Camp4 Therapeutics paid $11K out of pocket for Camp4 Therapeutics shares. 3 other people at Camp4 Therapeutics bought some too, in the same month.
Since the trade +36.3% · S&P 500 +4.9% · to Nov 20
A major shareholder of Camp4 Therapeutics paid $4.5M out of pocket for Camp4 Therapeutics shares. 6 other people at Camp4 Therapeutics bought some too, in the same month. It was the first purchase in 11 months.
Their first buy on recordTraded Sep 11, 2025 · filed the same day
Since the trade +36.3% · S&P 500 +4.9% · to Nov 20
A Camp4 Therapeutics director paid $25K out of pocket for Camp4 Therapeutics shares. 6 other people at Camp4 Therapeutics bought some too, in the same month. Shares held went up 10% with this purchase.
Their first buy on recordTraded Sep 11, 2025 · filed the same day
Since the trade +36.3% · S&P 500 +4.9% · to Nov 20
The CFO of Camp4 Therapeutics paid $10K out of pocket for Camp4 Therapeutics shares. 6 other people at Camp4 Therapeutics bought some too, in the same month. Shares held went up 10% with this purchase.
Their first buy on recordTraded Sep 11, 2025 · filed the same day
Since the trade +36.3% · S&P 500 +4.9% · to Nov 20
The CEO of Camp4 Therapeutics paid $10K out of pocket for Camp4 Therapeutics shares. 6 other people at Camp4 Therapeutics bought some too, in the same month.
Their first buy on recordTraded Sep 11, 2025 · filed the same day
Since the trade +36.3% · S&P 500 +4.9% · to Nov 20
Camp4 Therapeutics's Chief Medical Officer paid $10K out of pocket for Camp4 Therapeutics shares. 6 other people at Camp4 Therapeutics bought some too, in the same month.
Since the trade −64.7% · S&P 500 +19.0% · to Nov 20
A major shareholder of Camp4 Therapeutics paid $10M out of pocket for Camp4 Therapeutics shares. 6 other people at Camp4 Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Since the trade −64.7% · S&P 500 +19.0% · to Nov 20
A major shareholder of Camp4 Therapeutics paid $15M out of pocket for Camp4 Therapeutics shares. 6 other people at Camp4 Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Since the trade −64.7% · S&P 500 +19.0% · to Nov 20
A major shareholder of Camp4 Therapeutics paid $8.4M out of pocket for Camp4 Therapeutics shares. 6 other people at Camp4 Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Since the trade −64.7% · S&P 500 +19.0% · to Nov 20
A major shareholder of Camp4 Therapeutics paid $10M out of pocket for Camp4 Therapeutics shares. 6 other people at Camp4 Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Since the trade −64.7% · S&P 500 +19.0% · to Nov 20
A Camp4 Therapeutics director paid $10M out of pocket for Camp4 Therapeutics shares. 6 other people at Camp4 Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Since the trade −64.7% · S&P 500 +19.0% · to Nov 20
A Camp4 Therapeutics director paid $10M out of pocket for Camp4 Therapeutics shares. 6 other people at Camp4 Therapeutics bought some too, in the same month. It was the first purchase in over a year.
14 open-market purchases and 6 open-market sales by insiders of CAMP between Jul 15, 2025 and today, placed against the company's last 4 earnings releases. The latest on file was filed Aug 13, 2026. The data provider lists the next release for Mar 3, 2027; that date may change.
PurchaseSale30 days before a release30 days after
Trades in the 30 days around each of the last earnings releases
Kelly Gold, Chief Financial Officer, Aug 31, 2026, about $40K. Bought 18 days after the company's previous earnings release on 2026-08-13Form 4
Andrew J. Schwab, Director, Aug 27, 2026, about $1.62M. Sold 14 days after the company's previous earnings release on 2026-08-13Form 4
Andrew J. Schwab, Director, Aug 24, 2026, about $45. Sold 11 days after the company's previous earnings release on 2026-08-13Form 4
Andrew J. Schwab, Director, Aug 21, 2026, about $144K. Sold 8 days after the company's previous earnings release on 2026-08-13Form 4
Andrew J. Schwab, Director, Aug 20, 2026, about $521K. Sold 7 days after the company's previous earnings release on 2026-08-13Form 4
Andrew J. Schwab, Director, Aug 19, 2026, about $215K. Sold 6 days after the company's previous earnings release on 2026-08-13Form 4
Daniel Tardiff, Chief Scientific Officer, Aug 19, 2026, about $8.3K. Sold 6 days after the company's previous earnings release on 2026-08-13Form 4
Richard A Young, Director, Aug 3, 2026, about $27K. Bought 10 days before the company's next earnings release on 2026-08-13Form 4
Yuri Maricich, Chief Medical Officer, Aug 3, 2026, about $11K. Bought 10 days before the company's next earnings release on 2026-08-13Form 4
Kelly Gold, Chief Financial Officer, Aug 3, 2026, about $11K. Bought 10 days before the company's next earnings release on 2026-08-13Form 4
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies